F-PSMA-N5
Phase 1Small molecule
F-PSMA-N5 is one of 54 small molecule programs targeting Metastasis. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Metastasis
#DrugCompanyPhaseTrials
1Verzenio
Eli LillyApproved
Camptosar
PfizerApproved
Gemzar
Johnson & JohnsonApproved
Femara
NovartisApproved
Norvir
AbbVieApproved
Neoral
NovartisApproved
Tukysa
PfizerApproved
Lynparza
AstraZenecaApproved
Taxol
TevaApproved
Zometa
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Metastasis2 trials
Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Recruiting·—·Phase 1·NCT06462495·30 enrolled
Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Recruiting·—·Phase 1·NCT06462508·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F-PSMA-N5. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAnhui Provincial Hospital